Retatrutide vs Tirzepatide: Which One Is Better for Weight Loss?

| April 18, 2026

Medically reviewed and fact-checked

Evidence-Based Content

This article is grounded in the latest scientific research and clinical evidence. It has been carefully written by qualified professionals with subject-matter expertise and reviewed through a rigorous fact-checking process to ensure accuracy, relevance, and reliability.

We prioritize high-quality sources, including peer-reviewed studies, clinical guidelines, and established medical research, to provide information you can trust.

Our team is committed to maintaining the highest standards of integrity. Every piece of content is created with a focus on objectivity, transparency, and honesty. We aim to present balanced perspectives, including potential benefits, risks, and limitations, so readers can make well-informed decisions.

Summarize with AI Instantly break down this article

Free to use

Choose your AI assistant

ChatGPT

Perplexity

Claude

Grok

If you’ve been exploring medical weight loss options, you’ve likely come across the debate around retatrutide vs tirzepatide. Both medications are making waves in the world of obesity treatment. But they aren’t the same thing — and one of them isn’t even available yet.

This guide breaks down exactly how they differ, what the research shows, and what your real options are today.

What Is Tirzepatide?

Tirzepatide is an FDA-approved medication sold under two brand names:

Mounjaro — approved for type 2 diabetes (2022)
Zepbound — approved for chronic weight management (2023)

It works as a dual agonist, meaning it targets two hormone receptors: GLP-1 and GIP. These hormones help your body:

Feel full faster
Eat less
Regulate blood sugar
Improve metabolism

In the SURMOUNT-1 clinical trial, patients on 15 mg of tirzepatide lost an average of 20.9% of their body weight over 72 weeks. That’s roughly 48 pounds for someone weighing 230 pounds.

Tirzepatide is available right now by prescription. If you’re ready to explore your eligibility, you can learn more about tirzepatide treatment options with a licensed provider.

What Is Retatrutide?

Retatrutide is a newer investigational drug still in clinical trials. It is NOT yet FDA-approved.

It works as a triple agonist — targeting three hormone receptors: GLP-1, GIP, and glucagon. That third target (glucagon) may increase calorie burning and speed up fat breakdown.

In a Phase 2 trial, participants taking 12 mg of retatrutide lost an average of 24.2% of their body weight at 48 weeks. That’s higher than any currently approved weight loss drug.

However, Phase 3 trials are still ongoing. FDA approval is expected no earlier than late 2026 or 2027.

Retatrutide vs Tirzepatide: Head-to-Head Comparison

Here’s a simple breakdown of how the two drugs compare:

Feature	Tirzepatide	Retatrutide
FDA Approved	Yes	No (trials ongoing)
Mechanism	Dual agonist (GLP-1 + GIP)	Triple agonist (GLP-1 + GIP + Glucagon)
Weight Loss (Clinical)	Up to ~21%	Up to ~24%
Available by Prescription	Yes	No
Injection Frequency	Once weekly	Once weekly (in trials)
Long-term Safety Data	Established	Limited

How Do They Work Differently?

Think of it this way:

Tirzepatide uses two tools to help you eat less and burn energy.
Retatrutide adds a third tool — one that may boost your metabolism even further.

The extra glucagon receptor activity in retatrutide may help the body burn more fat. But this also means more potential for side effects, especially in early dose escalation.

A systematic review published in The NNT found that retatrutide (12 mg) achieved a 22% weight reduction from baseline, compared to 18% for tirzepatide — the highest of any agent in the review’s 26 included trials.

Which Drug Has More Side Effects?

Both drugs share similar side effects because they both activate GLP-1 receptors. Common side effects include:

Nausea
Diarrhea
Vomiting
Constipation
Stomach discomfort (usually during dose increases)

With retatrutide, the glucagon activation may add some additional effects like increased feelings of warmth or energy. Since long-term safety data is limited, close monitoring is especially important.

Rare but serious risks for both include pancreatitis, gallbladder issues, and possible thyroid concerns. Always discuss your full medical history with a provider before starting either medication.

Real Patient Experience: What Patients Report

One patient at a medical weight loss clinic described her tirzepatide experience:

“By week 12, my appetite had completely changed. I wasn’t obsessing over food the way I used to. I lost 22 pounds in the first three months and kept going from there.”

Retatrutide data from early trial participants shows similarly strong appetite suppression, with some reporting noticeable changes within the first few weeks.

What About Cost and Availability?

Tirzepatide Pricing

Since tirzepatide is FDA-approved and available today, here’s a quick snapshot of costs:

Brand name (Zepbound): ~$1,086/month list price
With commercial insurance + savings card: as low as $25/month
Through telehealth programs: starting around $299–$499/month

At Tirzepatide Medics, medically supervised tirzepatide programs are available with transparent, flexible pricing options designed to make treatment accessible.

Retatrutide Pricing

Retatrutide has no pricing yet — it’s not commercially available. Any website claiming to sell “retatrutide” outside of a clinical trial is selling an unapproved product. Avoid these sources entirely.

Can You Get Retatrutide Now?

Not through a regular prescription. The only legal way to access retatrutide right now is through an FDA-registered clinical trial.

If you want to start a medically supervised weight loss program today, tirzepatide remains the strongest FDA-approved option available. You can schedule a consultation to get started with a licensed provider.

Who Should Choose Tirzepatide Right Now?

You should consider tirzepatide if you:

Want an FDA-approved, proven option available today
Need to start treatment now without waiting
Have type 2 diabetes or weight-related health conditions
Prefer a medication with years of real-world safety data

Who Should Watch for Retatrutide?

Retatrutide may be worth watching if you:

Are already on tirzepatide and want to know what’s next
Are a healthcare provider tracking obesity medicine advances
Are interested in potentially enrolling in a Phase 3 clinical trial

The Bottom Line on Retatrutide vs Tirzepatide

When comparing retatrutide vs tirzepatide today, tirzepatide wins for one simple reason: it’s available. It’s FDA-approved, backed by years of clinical data, and delivering real results for real people right now.

Retatrutide shows tremendous promise. Its triple-agonist mechanism may eventually make it the gold standard in obesity treatment. But until Phase 3 trials are complete and the FDA reviews the data, it remains an exciting future option — not a current one.

If you’re ready to take a real step toward medical weight loss, access your personalized plan through the Tirzepatide Medics patient portal.

Frequently Asked Questions

Is retatrutide better than tirzepatide for weight loss?

Early trial data show retatrutide may produce slightly higher weight loss, but tirzepatide is FDA-approved and available now, making it the practical choice today.

Can I get retatrutide from my doctor?

No — retatrutide is still in clinical trials and cannot be prescribed by any provider as of 2026.

How much weight can I lose with tirzepatide?

In clinical trials, patients lost up to 20–21% of their body weight over 72 weeks at the highest dose.

Are retatrutide and tirzepatide the same drug?

No — they are different drugs; tirzepatide targets two hormone receptors while retatrutide targets three.

What are the side effects of both drugs?

Both share similar GI side effects like nausea, diarrhea, and vomiting, particularly during the early dose escalation phase.

When will retatrutide be FDA-approved?

FDA approval is expected no earlier than late 2026, pending completion of Phase 3 trials.

Sources

Rose Lane - Medical Writer

Rose Lane is an American medical writer and former physician with over twenty years of clinical experience, having earned her MD from NYU. Drawing on both her medical background and personal resilience, she is passionate about writing on modern weight loss and emerging treatments. She joined Tirzepatide Medics LLC in April as a Medical Writer, where she focuses on making complex health topics clear and accessible.

Important Medical Information and Disclaimers

Medical Disclaimer: The content on this page is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Tirzepatide is available in the United States as FDA-approved prescription medications—Mounjaro® (approved for type 2 diabetes) and Zepbound® (approved for chronic weight management and obstructive sleep apnea in adults with obesity). Always consult a licensed U.S. healthcare provider before starting any medication.

Source: U.S. FDA – Mounjaro Prescribing Information (PDF)

Individual Results May Vary: In U.S. clinical studies, results with tirzepatide varied significantly between participants. Effectiveness can depend on factors such as following the prescribed plan, maintaining healthy diet and exercise habits, individual metabolism, underlying health conditions, and emotional well-being.

Source: U.S. NIH – Clinical Trials on Tirzepatide

Possible Side Effects: The most common side effects reported in U.S. trials include nausea, vomiting, diarrhea, constipation, abdominal discomfort, decreased appetite, and mild injection-site reactions. Less common but serious side effects may include pancreatitis, gallbladder problems, acute kidney injury, hypoglycemia, and severe allergic or injection-site reactions.

Source: FDA – Safety Information & Postmarket Concerns

Thyroid Risk Warning: Animal studies have found an increased risk of thyroid C-cell tumors with tirzepatide use. It is not known if this applies to humans. Mounjaro® and Zepbound® should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Source: FDA – Mounjaro Labeling (PDF)
Source: FDA – Zepbound Labeling (PDF)

Compounded Versions Warning: The U.S. FDA has issued warnings about compounded tirzepatide, stating these versions may lack the safety, quality, and proven effectiveness of FDA-approved medications. Always obtain your medication from a licensed U.S. pharmacy.

Source: FDA – Compounding and the FDA: Questions and Answers

Reporting Side Effects: If you experience side effects while taking any prescription medication in the U.S., report them to the FDA MedWatch program at www.fda.gov/medwatch or call 1-800-FDA-1088. This helps ensure ongoing safety monitoring for all patients.